AbbVie (ABBV) Stock Forecast & Price Target

$176.95 +5.22 (+3.04%)

(As of 11/22/2024 ET)

AbbVie - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 23 Analyst Ratings

Sell
0

Hold
3

Buy
20

Based on 23 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 3 have given a hold rating, 18 have given a buy rating, and 2 have given a strong buy rating for ABBV.

Consensus Price Target

$203.50
15.00% Upside

According to the 23 analysts' twelve-month price targets for AbbVie, the average price target is $203.50. The highest price target for ABBV is $225.00, while the lowest price target for ABBV is $173.00. The average price target represents a forecasted upside of 15.00% from the current price of $176.95.

Get the Latest News and Ratings for ABBV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors.

ABBV Analyst Ratings Over Time

Type	Current Forecast 11/24/23 to 11/23/24	1 Month Ago 10/25/23 to 10/24/24	3 Months Ago 8/26/23 to 8/25/24	1 Year Ago 11/24/22 to 11/24/23
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	18 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	8 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$203.50	$198.47	$191.64	$167.69
Forecasted Upside	15.00% Upside	4.63% Upside	-2.99% Downside	20.88% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Shocking footage from Bill Gates’ $100,000,000,000 AI Bet (Ad)

If you missed out on Nvidia, watch this video I just made.

Click here for full details.

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AbbVie Stock vs. The Competition

Type	AbbVie	Medical Companies	S&P 500
Consensus Rating Score	2.96	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	15.00% Upside	27,098.21% Upside	7.66% Upside
News Sentiment Rating	Positive News See Recent ABBV News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/22/2024	Leerink Partnrs 5 of 5 stars	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
11/22/2024	Leerink Partners 1 of 5 stars		Upgrade	Market Perform ➝ Outperform	$206.00	+19.64%
11/19/2024	Wells Fargo & Company 3 of 5 stars		Boost Target	Buy	$195.00	+17.80%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$205.00	+20.85%
11/13/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$210.00 ➝ $200.00	+16.74%
11/12/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$226.00 ➝ $215.00	+24.27%
“This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad) Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in… >> YES! Send Me My FREE Gold Guide!
11/12/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$228.00 ➝ $208.00	+18.74%
11/12/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$231.00 ➝ $224.00	+28.41%
11/6/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$212.00 ➝ $221.00	+9.36%
11/4/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
10/31/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$195.00 ➝ $200.00	-1.87%
10/18/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$185.00 ➝ $195.00	+3.45%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$203.00	+6.58%
10/10/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$210.00 ➝ $215.00	+10.49%
10/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$200.00 ➝ $212.00	+9.75%
10/7/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$195.00 ➝ $225.00	+16.22%
8/30/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/23/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$196.00 ➝ $209.00	+6.05%
8/5/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$200.00 ➝ $200.00	+8.40%
7/3/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$190.00 ➝ $190.00	+14.48%
6/5/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$185.00	+14.08%
2/5/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$181.00 ➝ $189.00	+12.05%
12/11/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$173.00	+15.89%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$150.00	+5.60%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$170.00 ➝ $160.00	+18.02%
2/10/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$157.00 ➝ $154.00	+1.83%
2/10/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform	$135.00 ➝ $153.00	+2.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:02 PM ET.

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, November 21, 2024. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

AbbVie
Bull Case

Here are some ways that investors could benefit from investing in AbbVie:

AbbVie has a strong market position with a current stock price of $167.74, reflecting investor confidence and potential for growth.
The company recently reported earnings of $3.00 per share, exceeding analysts' expectations, which indicates robust financial performance and effective management.
AbbVie has received multiple upgrades from analysts, with Wells Fargo raising its price target to $195.00, suggesting a positive outlook and potential for stock appreciation.
Institutional ownership is high, with 70.23% of shares held by institutional investors, which often indicates stability and confidence in the company's long-term prospects.
AbbVie has a diverse product portfolio, including recent advancements in its pharmaceutical offerings, which can drive future revenue growth and market expansion.

AbbVie
Bear Case

Investors should be bearish about investing in AbbVie for these reasons:

The stock has experienced volatility, with a 52-week range between $137.14 and $207.32, indicating potential risks associated with price fluctuations.
AbbVie has a high debt-to-equity ratio of 9.64, which may raise concerns about financial leverage and the company's ability to manage its debt effectively.
Recent price target reductions from other analysts, such as Morgan Stanley lowering its target to $224.00, could signal caution among market experts regarding future performance.
The company's quick ratio of 0.54 suggests potential liquidity issues, meaning it may struggle to meet short-term obligations without additional financing.
AbbVie faces increasing competition in the pharmaceutical sector, which could impact its market share and profitability in the long run.

ABBV Forecast - Frequently Asked Questions

: According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $203.50, with a high forecast of $225.00 and a low forecast of $173.00.
: 23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 3 hold ratings, 18 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABBV shares.
: According to analysts, AbbVie's stock has a predicted upside of 15.00% based on their 12-month stock forecasts.
: Over the previous 90 days, AbbVie's stock had 4 upgrades by analysts.
: AbbVie has been rated by research analysts at Argus, Bank of America, Barclays, BMO Capital Markets, Citigroup, Guggenheim, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Sanford C. Bernstein, TD Cowen, Truist Financial, UBS Group, Wells Fargo & Company, William Blair, and Wolfe Research in the past 90 days.
: Analysts like AbbVie more than other "medical" companies. The consensus rating score for AbbVie is 2.96 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ABBV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Breaking News: Tesla headed to $500… (Ad)

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

This page (NYSE:ABBV) was last updated on 11/23/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Stock Forecast & Price Target